A STAT3-inhibitory hairpin decoy oligodeoxynucleotide discriminates between STAT1 and STAT3 and induces death in a human colon carcinoma cell line by Souissi, Inès et al.
RESEARCH Open Access
A STAT3-inhibitory hairpin decoy
oligodeoxynucleotide discriminates between
STAT1 and STAT3 and induces death in a human
colon carcinoma cell line
Inès Souissi
1,2, Patrick Ladam
2,6, Jean AH Cognet
7, Stéphanie Le Coquil
1,2, Nadine Varin-Blank
1,2,
Fanny Baran-Marszak
1,2,4, Valeri Metelev
5 and Remi Fagard
1,2,3*
Abstract
Background: The Signal Transducer and Activator of Transcription 3 (STAT3) is activated in tumor cells, and STAT3-
inhibitors are able to induce the death of those cells. Decoy oligodeoxynucleotides (dODNs), which bind to the
DNA Binding Domain (DBD) of STAT3, are efficient inhibitors. However, they also inhibit STAT1, whose activity is
essential not only to resistance to pathogens, but also to cell growth inhibition and programmed cell death
processes. The aim of this study was to design STAT3-specific dODNs which do not affect STAT1-mediated
processes.
Results: New dODNs with a hairpin (hpdODNs) were designed. Modifications were introduced, based on the
comparison of STAT3- and STAT1-DBD interactions with DNA using 3D structural analyses. The designed hpdODNs
were tested for their ability to inhibit STAT3 but not STAT1 by determining: i) cell death in the active STAT3-
dependent SW480 colon carcinoma cell line, ii) absence of inhibition of interferon (IFN) g-dependent cell death, iii)
expression of STAT1 targets, and iv) nuclear location of STAT3 and STAT1. One hpdODN was found to efficiently
induce the death of SW480 cells without interfering with IFNg-activated STAT1. This hpdODN was found in a
complex with STAT3 but not with STAT1 using an original in-cell pull-down assay; this hpdODN also did not inhibit
IFNg-induced STAT1 phosphorylation, nor did it inhibit the expression of the STAT1-target IRF1. Furthermore, it
prevented the nuclear transfer of STAT3 but not that of IFNg-activated STAT1.
Conclusions: Comparative analyses at the atomic level revealed slight differences in STAT3 and STAT1 DBDs’
interaction with their DNA target. These were sufficient to design a new discriminating hpdODN that inhibits
STAT3 and not STAT1, thereby inducing tumor cell death without interfering with STAT1-dependent processes.
Preferential interaction with STAT3 depends on oligodeoxynucleotide sequence modifications but might also result
from DNA shape changes, known to modulate protein/DNA interactions. The finding of a STAT3-specific hpdODN
establishes the first rational basis for designing STAT3 DBD-specific inhibitors.
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Background
STAT3 belongs to the signal transducers and activators
of transcription (STATs) family of transcription factors
(TFs) [1]. STAT3 is activated in response to several
cytokines and growth factors, including IL-6, IL-10, the
epidermal growth factor (EGF), and interferon (IFN) a
and is also weakly activated in response to other cyto-
kines, including IFNg in some cellular contexts [2]. Acti-
vation of STAT3 involves phosphorylation of tyrosine
705 by cytokine receptor-associated Janus Kinases (JAK);
the involvement of the Src and Abl tyrosine kinases as
well as EGFR have also been reported [3]. Tyrosine
phosphorylation of STAT3 is followed by dimerization
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vated STAT3 enters the nucleus where it stimulates the
transcription of its targets, including Cyclin-D1, Survi-
vin, Vegf, C-Myc, Bcl-xL, and Bcl2 [4,5].
STAT3 is a key regulator of cell survival and prolifera-
tion [6]. Its constitutive activation has been observed in
many human tumors, including colon, breast, lung, pan-
creas and prostate cancers, melanoma, head and neck
squamous carcinoma, multiple myeloma, mantle cell
lymphoma, and glioma [7,8]. However, in certain cell
types such as PTEN-deficient glioblastoma, STAT3 can
become a tumor suppressor [9,10].
STAT1 is another member of the STAT family. It is
activated mainly by IFNs a and g, and plays a major
role as a pro-inflammatory, anti-pathogen and anti-pro-
liferative factor [11,12]. Its biological function is thus
mostly antagonistic to that of STAT3. Despite their 50%
amino acid sequence homology [13], STAT1 and
STAT3 are structurally very similar; yet some important
differences have been noted in their DBD sequences
[14]. Despite its major role as a tumor antagonist,
STAT1 can also have functions in cancer cells, as docu-
mented in mouse leukemia [15].
Inhibition of STAT3 in tumor cells in which it is consti-
tutively activated leads to cell death [16-18]. This is
achieved using either non-specific inhibitors such as cur-
cumin, which also inhibits other transcription factors (NF-
B), or inhibitors specifically designed to inhibit STAT3
through non-covalent binding to the SH2 domain, such as
Stattic [19] or STA-21 [20]. Interestingly, these com-
pounds have little effect in cells in which STAT3 is not
activated, pointing to STAT3 as a highly valid target to
focus on for the design of anti-cancer compounds. How-
ever, such compounds are still poorly developed.
TFs activate transcription of their target genes by
binding to distinct short DNA consensus motifs. Decoy
oligonucleotides (dODNs) containing these consensus
motifs can bind the DNA binding domains (DBD) of the
TFs and block their activity. dODNs [21] and hairpin
dODNs (hpdODNs) [22] have been shown to induce the
death of cells in which STAT3 is activated, suggesting
that the DBD is another potential target for specific
inhibitory compounds. Similarly to double-stranded oli-
gonucleotides that are used to detect active dimers in
electrophoretic migration shift assays, STAT3 hpdODNs
interact with activated, dimeric STAT3. This interaction
impairs the binding of the dimer to importins, resulting
in the sequestration of STAT3 in the cytoplasm [23].
Yet, because of the high degree of similarity between
STAT3 and STAT1 consensus DNA binding sites,
STAT1 competes with activated STAT3 for dODN
binding in interferon (IFN) g-treated cells [22,23],
thereby preventing inhibition of active STAT3. Under
such conditions the dODN loses its ability to block cell
proliferation. In addition, since STAT1 plays a key role
in cell death processes [24,25], including caspases
expression [26,27] and cooperation with p53 function
[28,29], its inhibition by the dODN prevents cell death.
Finally, IFNg being a cell death inducer in several cell
types [22,30-32], it is important to design reagents that
do not interfere with STAT1, one of its key effectors.
Thus, in order to elaborate target-specific anti-cancer
compounds, the specificity of hpdODNs to STAT3
needs to be enhanced. It should be noted, however, that
in certain cellular contexts STAT1 has been found to be
a tumor promoter [15].
The difficulty in designing dODNs recognized by
STAT3 but not STAT1 lies in the striking similarity of the
consensus DNA sequences of the two TFs [33], in spite of
their different cellular functions. Nevertheless, early stu-
dies on STAT3/STAT1-discriminating DNA motifs estab-
lished some sequence preferences that differentiate these
TFs [34-39], suggesting possibilities for designing STAT3/
STAT1-discriminating dODNs. The notion that discrete
nucleotide modifications in target DNA sequences might
alter their recognition by closely related TFs is supported
by the observation that a single nucleotide change in the
B consensus motif modified NF-B subunit specificity
[40]. Furthermore, DNA recognition by proteins relies in
part on DNA shape, known to deviate from the ideal B-
conformation. The nature of the nucleotides in the
sequence influences conformation and dynamics: for
instance, dG:dC stretches confer rigidity [41], pyrimidine/
purine steps (particularly T/dA steps) confer flexibility and
may also introduce kinks [42,43], and dA:T stretches can
have complex configurations [41]. The coordinates from
available crystal structures of both STAT1 [44] and
STAT3 [45] (in complex with their DNA consensus
sequence) were used to analyze their 3D structure using
the UCSF Chimera program [46]. Based on the differences
found, new hpdODNs were designed and tested for their
STAT3/STAT1 discrimination ability by measuring
SW480 colon carcinoma cell death and absence of inhibi-
tion of STAT1-dependent IFNg-induced cell death.
SW480 cells offer a relevant model since these cells show
constitutive activation of STAT3, which is essential for
their survival, and they are susceptible to IFNg-induced
cell death, which is a STAT1-dependent process. The
newly designed hpdODNs were also compared for their
relative binding capacity to STAT1 and STAT3 by per-
forming in-cell pull-downs, and for their ability to prevent
nuclear transfer using immunofluorescence.
Results
Striking similarities in the interactions of STAT1 and
STAT3 with their consensus DNA sequence
Comparison of the 3D structures of STAT1 and STAT3
in complex with their oligonucleotide duplexes featuring
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Page 2 of 12a consensus DNA sequence using the Chimera program
showed that they are highly similar (Figure 1A), with an
overall root mean square dev i a t i o no f0 . 6 3Åb e t w e e n
317 atom pairs of the backbone. To focus our study on
the interaction of the STAT1 and STAT3 DBDs with
their consensus DNA sequence, only the amino acids in
c l o s ec o n t a c tw i t ht h eD N As t r a n d sw e r ee x a m i n e d .
This revealed the striking similarity of STAT1 and
STAT3 DNA-interacting amino acids (Figures 1B and
1C). Several differences were noted, however, including:
Figure 1 3D comparison of STAT1 and STAT3 and of their DNA binding region. A: View of the superimposed 3D structure of STAT1 and
STAT3 monomers created with the Chimera program, showing the DNA binding region. B and C: close-up views of the DNA binding regions of
STAT1 (B) and STAT3 (C). Amino acids shown are those within a 5 Å distance from DNA; note that Thr 327 did not appear using this selection
and was added. Arrows point to amino acids of STAT1 and STAT3 interacting differently with DNA.
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H-bond distance from G 1017 [44], G 2002 and C 1018
(the latter possibly mediated by water) (Figures 1B and
1C; detailed view in Figure 2; see Table 1 for a list of H-
bonds and Additional file 1: Table S1 for a list of the
interactions of STAT1 and STAT3 with DNA); ii) the
peptide backbone of a polar residue of STAT1, Thr 327,
and of a hydrophobic residue of STAT3, Met 331, estab-
lish H bonds with C 1009 and C 1010 (Figure 1B); iii) a
polar amino acid, Thr 419 for STAT1, and a charged
amino acid, Arg 423 for STAT3, are identically posi-
tioned, facing the backbone of nucleotide 1018 (Figure
1B). To obtain STAT3/STAT1 discriminating sequences,
we chose to design hpdODNs, by modifying the original
consensus sequences at the specific positions where
interactions with STAT1 and STAT3 were found to dif-
fer (the consensus sequences and hpdODNs are
depicted in Figure 3: for convenience we use the same
numbering as in reference [45]).
Nucleotide substitutions provide a hairpin decoy
oligonucleotide which can discriminate between STAT1
and STAT3, inhibiting STAT3 in IFNg-treated cells
As previously shown [22,23], the consensus-carrying
hpdODN A can efficiently induce the death of cells of the
SW480 line (Figure 4A and 4B); but it also inhibits
STAT1, thus blocking the STAT1-dependent IFNg-
induced mortality of these cells (Figure 4A, B and 4C) as
previously shown [22,23]. hpdODN B was designed by
replacing three base pairs in hpdODN A. T replaced dC in
position 1003, dC replaced dG in 1011, and dG replaced
dC in position 1017 (Figure 3). In the same assay,
hpdODN B was found to efficiently induce SW480 cell
death but was devoid of any action on IFNg-induced cell
death (Figure 4A and 4B), indicating a preference for
STAT3 over STAT1. Features of hpdODN B consist in a
stretch of pyrimidines spanning nucleotides 1005 to 1012,
a d(TA) step (1003/1004) and a d(TG) step (1016/1017).
To analyze the possible effect of only one change in the
sequence of hpdODN A, hpdODN C was designed by
replacing dG with dC in position 1011 (Figure 3). The kill-
ing efficiency of HpdODN C was lower than those of
hpdODN A [22,23] and hpdODN B, but in contrast with
the latter, it showed a capacity to compete with IFNg-
induced mortality, suggesting that it interacts with STAT1
(Figure 4A and 4B). Next, by placing dG in 1003, dC in
1004, dC in 1011 and dG in 1017 we obtained hpdODN D
(Figure 3), which corresponded with a sequence with a
marked preference for STAT1 as previously shown by
others using a reporter assay [47]. hpdODN D did not
induce SW480 cell mortality, but prevented IFNg-induced
killing (Figure 4A and 4B). Finally, hpdODN E, containing
a mutated STAT3 binding site (Figure 3) did not induce
cell death and did not compete with IFNg-induced cell
death (Figure 4A and 4B). A comparison of the different
hpdODNs’ IFNg-independent cell killing efficiency (taking
the killing efficiency of hpdODN A as the 100% standard)
showed that hpdODN B was twice as efficient as hpdODN
A (Figure 4C) and that the control mutated hpdODN E
had no effect on cell death (Figure 4C), as previously pub-
lished [22,23].
The new STAT3-specific hpdODN B inhibits STAT3 but not
STAT1 phosphorylation and inhibits cyclin D1 but not
IRF1 expression
To detect the effect of the hpdODNs on STAT3 phos-
phorylation, IL-6-treated (50 ng/ml) SW480 cells were
used. In cells treated with hpdODN B and hpdODN A
for 16 h, STAT3 phosphorylation was suppressed (Fig-
ure 4E, lanes 2 and 3); the expression of cyclin D1 and
of STAT3 itself (STAT3 being its own target) were con-
siderably diminished (Figure 4E, lanes 2 and 3), in
agreement with previous observations [22,23]. When
cells were treated for 4 h with hpdODNs A and B, phos-
pho-STAT3 was reduced without effect on STAT3 (Fig-
ure 4F); the control mutated hpdODN E had no effect
(Figures 4E and 4F, lane 4). To confirm that hpdODN B
was preferentially inhibiting STAT3 in SW480 cells, the
induction of the STAT1-dependent IFNg target IRF1
was studied. In cells treated with IFNg (50 ng/ml for 16
h), both phosphorylation of STAT1 and expression of
IRF1 increased (Figure 4D, lanes 1 and 2). Treatment
with hpdODN A, but not hpdODN B, strongly reduced
IRF1 expression (Figure 4D, lanes 3 and 4). In IFNg-
treated cells, the addition of hpdODN A reduced IFNg-
induced IRF1 expression (lane 5) whereas the addition
of hpdODN B did not (lane 6). Interestingly, STAT1
Figure 2 Location of Glu 421 (STAT1). A detailed view of the
close interactions of Glu 421 of STAT1 with C 1018, G 1017 and G
2002 in the minor groove of the double helix.
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treatment with hpdODN A (lane 5) but not with
hpdODN B (lane 6). These data indicate that under
these experimental conditions hpdODN B does not inhi-
bit STAT1.
Biotinylated hpdODN B interacts preferentially with
STAT3
Binding of STAT3 and STAT1 to hpdODNs has pre-
viously been analyzed directly within cells using
biotinylated versions of the different hpdODNs [23]. To
compare hpdODNs A and B, cells were treated, or not,
with IFNg, transfected with biotinylated hpdODNs, and
pull-downs were performed. The pull-down efficiencies of
h p d O D NA( F i g u r e5 ,l a n e s1a n d4 )a n dB( F i g u r e5 ,
lanes 3 and 6) for STAT1 and STAT3 were very different.
Indeed, compared with hpdODN A, hpdODN B brought
down STAT3 very efficiently, but not STAT1 (Figure 5,
lanes 1 and 3), even in IFNg (50 ng/ml) -treated cells (Fig-
ure 5, compare lanes 4 and 6). Furthermore, compared
Table 1 Hydrogen bonds involved in the interaction of STAT1 and STAT3 with DNA
STAT1 STAT3
Nucleotide involved Residue(s) involved Nucleotide involved Residue(s) involved
T 1005 Thr 427 (BB/Phos.) T 1005 Val 432 (BB/Phos.)
T 1006 Lys 413 (BB/Phos.) T 1006 Ser 465 (SC/Phos.)
Ser 459 (BB/Phos.) T 1006 Arg 382 (SC/Phos.)
Arg 378 (BB/Phos.) T 1006 Gln 469 (SC/Phos.)
Ser 459 (BB/Phos.) T 1006 Ser 465 (SC/Phos.)
Gln 463 (BB/Phos.)
T 1007 Asn 460 (BB/Base) T 1007 Asn 466 ND2(SC/Base)
T 1007 Arg 417 NH1 (SC/Phos.)
C 1008 Gln 344 NE2 (SC/Phos.)
C 1009 Gln 344 N (BB/Phos.)
C 1010 His 328 (SC/Phos.) C 1010 Lys 340 (SC/Phos.)
C 1010 His 332 (SC/Phos.)
G 1011 Lys 567(SC/Phos.)
T 1012 Asn 460 (SC/Base) T 1012 Asn 466 (SC/Base)
G 1017 Glu 421 (SC/Base)
C 1018 Thr 419 (BB/Phos.)
Thr 419 (BB/Phos.)
G 2002 Glu 421 (SC/Base)
Glu 421 (SC/Base)
T 2005 Thr 427 (BB/Phos.) T 2005 Val 432 (BB/Phos.)
T 2006 Lys 413 (SC/Phos.) T 2006 Ser 465 (SC/Phos.)
Arg 378 (SC/Phos.) T 2006 Arg 382 (SC/Phos.)
Ser 459 (SC/Phos.) T 2006 Ser 465 (SC/Phos.)
Arg 378 (SC/Phos.) T 2006 Gln 469 (SC/Phos.)
T 2007 Asn 460 (SC/Base) T 2007 Asn 466 (SC/Base)
Lys 413 (SC/BB) T 2007 Arg 417 (SC/Phos.)
A 2008 Asn 460 (SC/Base) A 2008 Gln 344 (SC/Phos.)
C 2009 Gln 344 (BB/Phos.)
G 2010 His 328 (SC/Phos.) G 2010 Lys 340 (SC/Base)
G 2010 His 332 (SC/Phos.)
G 2010 Lys 340 (SC/Phos.)
G 2011 Lys 567 (BB/Phos.)
G 2012 Asn 460 (SC/Base) G 2012 Asn 466 (SC/Base)
A 2013 Asn 460 (SC/Base)
G 2018 Glu 421 (SC/Phos.)
The nucleotides that are involved in binding with STAT1 or STAT3 are listed. For clarity, the numbering used is the same as in reference [45] (see Figure 3). The
following abbreviations were used for the atoms involved in hydrogen bonding: phospho-diester (Phos.) or base moiety (Base) for the nucleotides. BB stands for
backbone and SC for side-chain for the proteins.
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Page 5 of 12with hpdODN A, hpdODN D, shown to interact preferen-
tially with STAT1, was more efficient in pulling down
STAT1 than STAT3 (compare lanes 8 and 9 with lanes 1
and 4). Finally, hpdODN E, a control hpdODN with muta-
tions in the binding consensus, did not bring down either
STAT1 or STAT3 (Figure 5, lane 7).
The new hpdODN B prevents the constitutive nuclear
location of STAT3 in SW480 cells, but not that of IFNg-
activated STAT1
HpdODNs A and B were further compared for their abil-
ity to prevent the nuclear translocation of STAT3 and
STAT1 in SW480 cells (treated or not with IFNg)u s i n g
immunofluorescence. Treatment of the cells with
hpdODN A prevented the nuclear translocation of both
STAT3 and STAT1 (for STAT1 nuclear translocation,
IFNg-treated cells were used) (Figure 6), as previously
shown [22,23]. Treatment with hpdODN B prevented the
nuclear translocation of STAT3 only, and not that of
IFNg-activated STAT1 (Figure 6, columns 1 and 4, see
arrows), confirming its discriminative capacity. Notably,
the control mutated hpdODN E had no effect on the sub-
cellular location of either STAT3 or STAT1, which both
remained nuclear (Figure 6, columns 2 and 5).
Discussion
A new hairpin decoy oligonucleotide (hpdODN) carry-
ing STAT3’s DNA binding consensus sequence was
designed following 3D analysis of protein/DNA interac-
tion and shown to induce the death of STAT3-depen-
dent tumor cells without interfering with STAT1, a key
effector of cell death. In this paper, 3D structural ana-
lyses of the protein/DNA interaction of STAT1 and
STAT3 demonstrated their high similarity, confirming
previous reports [13]. These 3D analyses served as a
basis for the design of new sequences with base substi-
tutions. The new sequences were tested for their ability
to induce cell death in an IFNg-sensitive [22,23,48-51],
active-STAT3-dependent colon carcinoma cell line [22].
This enabled the design of the STAT3-specific hpdODN
labeled here as hpdODN B. The ability of hpdODN B to
discriminate between STAT1 and STAT3 was assessed
by: i) its ability to kill cells without interfering with
IFNg-induced cell death; ii) its ability to inhibit STAT3
targets, including cyclin D1, iii) the absence of inhibition
of IFNg-induced STAT1 phosphorylation and IRF1
expression, iv) its lack of interaction with STAT1 in
pull-down assays and iv) its inability to inhibit IFNg-
induced STAT1 nuclear location. Indeed, hpdODN A
treatment, but not hpdODN B treatment, reduced
STAT1 phosphorylation, probably by impairing nucleo-
cytoplasmic shuttling as previously suggested [22,23].
Nevertheless, despite its ability to discriminate between
STAT1 and STAT3, hpdODN B probably has a residual
affinity for STAT1, as shown by low detection of
STAT1 in pull-down assays and the fact that cell death
induction by hpdODN B and IFNg are not additive.
The STAT3/STAT1-discriminating hpdODN was
obtained by replacing key nucleotides that 3D analyses
had shown to be in the vicinity of amino acids of the
DBD that distinguish the two STATs; the similarity of
their DNA consensus sequences, despite their different
functions, has been recognized for some time [33].
Examination of the nucleotide modifications that led to
STAT1/STAT3-discriminating hpdODN B showed that
they are compatible with previous in vitro DNA-binding
studies, such as the preference for T at 1003 and 1005,
dC at 1010 and dA at 1015 of STAT3 [36-38]. The fact
that T at 1003 does not favor STAT1 binding is also in
agreement with the earlier suggestion that “selection for
a dG:dC base pair at position 7 (here: 1017) is likely to
involve Glu 421 (of STAT1) which can accept hydrogen
bonds from guanine in the minor groove” [44]. This has
also been noted by others [39]. Finally, altered recogni-
tion by a TF following single nucleotide changes has
been previously shown, for instance with NF-B subunit
recognition of B [40]. One notable property of the
hpdODN B is its dissymmetry. A symmetric version
(with dA replacing dG in 1017) was tested and is appar-
ently not different from hpdODN B (not shown). Intri-
guingly, although the preference of hpdODN D for
STAT1 was expected from previous data showing its
Figure 3 Sequences used in this study. The first two sequences
depicted are the ones used in the X-ray crystallographic studies of
STAT3 [45] and STAT1 [44], based on a STAT3 consensus sequence
derived from the c-fos gene promoter [34,35] and a STAT1
consensus sequence derived from the IRF-1 gene promoter
[34,35,59]. For clarity, the same numbering (shown here above the
STAT1 consensus sequence) was used for all sequences throughout
the study. Bases of the consensus sequence are in italic. HpdODN A
contains the optimal STAT3 consensus sequence based on the
STAT3 binding consensus [34], used in [21,22]. Compared with
hpdODN A, hpdODN B is modified at three locations: 1003, 1011
and 1017; hpdODN C is modified at 1011 only; and hpdODN D is
modified at 1003, 1004, 1011 and 1017. HpdODN E is a mutated
negative control which is modified at 1004, 1005, 1008, 1011, 1012,
1015, 1016 and 1017. Modified bases are in bold.
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Page 6 of 12Figure 4 Comparative cell death induction efficiency of the different hpdODNs in the presence or not of IFNg in the SW480 cell line.
The efficiencies of hpdODN A, B, C D and E in inducing cell death were compared, in the presence (+) or not (-) of IFNg. A. Cell death,
measured by determining propidium iodide (PI) labeling, induced by hpdODNs A to E (2 μg/ml) alone (-) or in the presence of IFNg (50 ng/ml
16 h) (+). B. Cell death, measured with flow cytometry for annexin V, induced by hpdODNs A to E (2 μg/ml) alone (-), or in the presence of IFNg
(50 ng/ml 16 h) (+). In A and B, FITC denotes the detection of cells having incorporated the fluorescein-labelled hpdODNs. Note that
experimental conditions were such that cell death was not maximal, to allow detection of differences between experiments. Experiments were
repeated at least three times, a typical result is shown. C: Histograms from several experiments (at least three per condition) using hpdODNs A
to E, obtained by computing PI incorporation and annexin V labelling data (such as those shown in Figures 4A and B). To facilitate comparison,
data are presented as% of the control. D: Western blotting showing the phosphorylation of STAT1 on tyrosine ("P-STAT1”) and expression level of
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Page 7 of 12STAT1-specific binding [47], its basis is not clear and
may rest upon properties beyond nucleotide sequence
such as DNA shape. The shape and flexibility of DNA
strands are known to be influenced by their nucleotide
content; here the 8-pyrimidine stretch in hpdODN B
may confer a higher flexibility than hpdODN A and
may account for a differential interaction with STAT3
Arg 423 and STAT1 Glu 421. In fact, the molecular
dynamics studies which describe a scissor-like molecular
movement upon DNA binding for STAT3, but not for
STAT1 [13] suggest that the flexibility of the DNA tar-
get may play a role in binding and therefore underly the
preference of hpdODN B for STAT3. It may also
account for the greater sensitivity of STAT3 to an intact
palindromic structure compared to STAT1, as pre-
viously stated [38]. Protein binding itself can affect DNA
bending, as shown with the high-affinity target of the
papillomavirus E2 [52]. Nevertheless, despite its effi-
ciency, the precise mechanism whereby the hpdODN B
discriminates between STAT1 and STAT3 in cells is not
understood. Changes in DNA shape may play a role in
the preferential recognition of hpdODN B by STAT3;
co-factors may also be involved in DNA recognition by
STAT3, and might associate more efficiently when
hpdODN B is used. The process might also be more
complex than mere differential DNA binding: STAT1
and STAT3 are reciprocally regulated [2,53-55] and the
relative abundance of their active forms may itself play a
key role in biological responses, as previously discussed
[56]. Another level of complexity arises from the fact
that in cells in which STAT3 has been suppressed,
IFNg-activated STAT1 induces the expression of mito-
genic STAT3-targets [57,58]. Furthermore, STAT1 and
STAT3 form heterodimers, whose function has not been
elucidated to date. In this respect, quantification of the
relative amounts of STAT1 and STAT3 bound to the
hpdODNs A and B may help understand the complex
interaction of these TFs. Preliminary experiments that
a r eu n d e r w a ys u g g e s tad i f f e r e n c ei nh e t e r o d i m e rc o n -
tent. Therefore, it is possible that hpdODN B functions
in cells by tilting the active STAT1/active STAT3 bal-
ance toward STAT1, thereby inducing cell death.
Conclusions
By combining 3D molecular interaction analysis and
direct screening in cells, this work allowed the design of
an hpdODN that can selectively inhibit STAT3 but not
STAT1. The efficacy and potential of this approach
resides in the direct testing of modified hpdODNs in
cells, analyzing processes that depend on STAT3 (cell
Figure 5 Specific binding of hpdODN B to STAT3 detected by in-cell pull-down. Western-blotting of STAT1 and STAT3 bound to
biotinylated hpdODNs after transfection and in-cell pull-down with avidine-coated beads. Cells were either not treated (-) (lanes 1, 2, 3 and 7, 8)
or treated (+) (lanes 4, 5, 6 and 9) with IFNg (50 ng/ml, 16 h), and hpdODN A (lanes 1 and 4), hpdODN B (lanes 3 and 6), hpdODN C (lanes 2
and 5) hpdODN D (lanes 8 and 9) and hpdODN E (lane 7) (hpdODNs were at 1 μg/ml for 16 h). Following cell lysis, protein concentration was
measured, identical amounts of protein per sample (250 μg) were added; anti-tubulin western blotting from aliquots of the extracts was
performed to show identical loading. Binding experiments were repeated at least three times. All lanes are part of the same blot (identical
exposure time) and have been separated for clarity.
IRF1 in the absence (lanes 1, 3 and 4) or presence of IFNg (50 ng/ml, 16 h) (lanes 2, 5 and 6) and in the presence or not of the indicated
hpdODNs (2 μg/ml). Anti-phospho-STAT1, anti-STAT1, anti-IRF1 and anti-tubulin antibodies were used. Experiments performed with the mutated
control hpdODN E showed no effect (not shown). E: Western blotting showing the inhibition of STAT3 phosphorylation and the reduced
expression of cyclin D1 and STAT3 following treatment with hpdODN A (lane 2) or hpdODN B (lane 3), or the mutated hpdODN E (lane 4) (2
μg/ml for 16 h). F: Western blotting showing the inhibition of STAT3 phosphorylation following treatment with hpdODN A (lane 2) or hpdODN
B (lane 3), or the mutated hpdODN E (lane 4) (2 μg/ml for 4 h). Experiments were repeated at least three times, one representative experiment
is shown.
Souissi et al. Molecular Cancer 2012, 11:12
http://www.molecular-cancer.com/content/11/1/12
Page 8 of 12survival) or STAT1 (IFNg-mediated death). These
hpdODNs represent a basis for elaborating STAT3
DBD-specific low molecular weight compounds with
anti-cancer properties.
Material and methods
Computer analysis of STAT3 and STAT1
The PDB (Protein Data Base) files for STAT1 (1BF5)
[44] and STAT3 (1BG1) [45] were downloaded and ana-
lyzed using Chimera [46]. The STAT1 and STAT3 crys-
tals used in the X-ray diffraction studies were proteins
complexed with oligonucleotide duplexes featuring a
consensus DNA sequence [34,35,59] (see Figure 3). To
compare the STAT1 and STAT3 DBDs in a complex
with their DNA consensus sequences, the missing com-
plementary strand of the STAT3-bound oligonucleotide
[45] was reconstructed through crystal symmetry
operations.
Decoy oligonucleotides
The STAT3 decoy ODNs used were
RHN-(CH2)6-CATTTCCCGTAAATCGAAGATT-
TACGGGAAATG-(CH2)6-NHR (STAT3 decoy
hpdODN), derived from the serum-inducible element of
the human c-fos promoter [34] (hpdODN A) and pre-
viously used in the lab [22,23].
RHN-(CH2)6-TATTTCCCCTAAATGGAACATT-
TAGGGGAAATA-(CH2)6-NHR (hpdODN B); RHN-
(CH2)6-CATTTCCCCTAAATCGAAGATTTAGGG-
GAAATG-(CH2)6-NHR (hpdODN C); RHN-(CH2)6-
GCTTTCCCCTAAATGGAACATTTAGGGGAAAGC-
(CH2)6-NHR (hpdODN D); and the following mutated
hpdODN as a negative control:
RHN-(CH2)6-CGATTGCCACAATCGGAACGATTG
TGGCAATCG-(CH2)6-NHR (hpdODN E) (where R was
either: hydrogen, fluorescein or biotin). The addition of
fluorescein or biotin, followed by high-performance
liquid chromatography, were carried out by the manu-
facturer (Eurogentec, Seraing, Belgium) using in-house
protocols. The hairpin sequence GAA, previously shown
to confer stability and nuclease resistance [60,61], was
included in the dODNs. In the hpdODNs, the hairpin
motif was built and incorporated in the X-ray structure
using the BCE (Biomolecular Chain Elasticity) approach
[62]; this showed that the hairpin did not interfere with
the DBD-DNA interaction (not shown).
Cell culture and reagents
SW480 (colon adenocarcinoma) cells were grown in
DMEM (Invitrogen, Lifetechnologies, Cergy-Pontoise,
France), supplemented with 10% FCS (Lonza, Levallois-
P e r r e t ,F r a n c e ) ,1 0 0U / m lp e n i c i l l i n ,1 0μg/ml strepto-
mycin (GibcoBRL), 1 mM sodium pyruvate (GibcoBRL),
MEM vitamins (100x, Invitrogen) and 5 μg/ml plasmo-
cin (Cayla InvivoGen, Toulouse, France). Sodium ortho-
vanadate (100 μM) was from Fischer (Illkirch, France).
Interferon g (50 ng/ml) was from Promocell (GmbH,
Heidelberg, Germany) or Sigma-Aldrich (Montigny-le-
Bretonneux, France).
Transfections
Cells were grown in 4-well plates to a density of 0.25 ×
10
6 cells/ml. When the cells reached 50-60% confluence,
they were transfected with the different STAT3
hpdODNs or the control hpdODN (2 μg/ml, corre-
sponding to 400 nM) into 150 μLo fD M E Mm e d i u m
(without SVF) combined with polyethyleneimine (PEI,
reference 408727, average MW: 25000, Sigma-Aldrich),
with an hpdODN/PEI ratio of 1:1. For immunocyto-
chemistry, liposomes prepared as previously described
[23] were used (at 2 μg of cationic lipid). After 6 h at
37°C in a humidified 5% CO2 incubator, the cells were
placed in fresh serum-containing medium. Cells were
examined after 48 h in the humidified incubator.
Flow cytometry and cell viability
To measure cell death, cells were resuspended in
annexin V-binding buffer, incubated with 5 μL of propi-
dium iodide (PI, BD Pharmingen, Morangis, France) and
subjected to flow cytometry analysis, using a FACS
Figure 6 Differential inhibition of STAT1 and STAT3 nuclear
transfer by hpdODN B. Immunofluorescence analysis of STAT1 and
STAT3 nuclear transfer in SW480 cells incubated with fluorescein-
labelled hpdODNs A, B and E (green). STAT1 nuclear transfer was
induced by treating cells with IFNg (50 ng/ml, 16 h) (columns 1, 2
and 3). Columns 3 and 6: hpdODN A; columns 1 and 4: hpdODN B;
columns 2 and 5: hpdODN E (mutated control). All hpdODNs were
at 1 μg/ml. STAT1 and STAT3 were detected using specific antibody
and a second rhodamine-coupled antibody (red), nuclei (blue) were
stained using DAPI and detected under UV light; the different
images were merged to examine the subcellular location of the
fluorescein-tagged hpdODNs (green) and STAT1 or STAT3 (red).
Arrows point to nuclear STAT1 and cytoplasmic STAT3 in IFNg-
treated and hpdODN B-treated cells. Size bar: 10 μm. One
representative experiment out of at least three is shown.
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lysis of the cells that had incorporated the various
hpdODNs, fluorescein-labelled hpdODNs were used.
Fluorescein-labelled cells were analyzed for PI incor-
poration (red channel) or annexin V labelling (APC, red
channel). A cell death index was established through
computation of averages.
Gel electrophoresis, western blotting
Cells were washed in Phosphate-Buffered Saline (PBS),
lysed in sodium dodecyl sulfate (SDS) sample buffer (50
mM Tris-HCl pH 6.8 (Bio-Rad, Marnes-la-Coquette,
France), 2% SDS (Sigma-Aldrich), 20% glycerol (Prolabo,
Fontenay-sous-Bois, France), 1 mM sodium vanadate
(Na3VO4, Labosi, Elancourt, France), 1 mM dithiothrei-
tritol (DTT) (Merck, Fontenay-sous-Bois, France) and
0.01% bromophenol blue (Sigma-Aldrich)), sonicated
a n ds t o r e da t- 7 0 ° C .P r o t e i n s( 5 0μg) were separated on
SDS polyacrylamide gels (PAGE) (10%) and transferred
onto nitrocellulose membranes; membranes blocked
with dry skimmed milk (5%) in Tris Buffered Saline
(TBS) were incubated with antibody overnight at 4°C.
Anti-phospho-STAT1, anti-STAT1 and anti-STAT3
(1:1000) (Cell Signaling, Ozyme, Montigny-le-Breton-
neux, France), anti-cyclin D1 and anti-IRF1 (1:1000)
(Santa Cruz, Tebu-bio, Le Perray en Yvelines, France)
were used. Blots were washed in TBS with Tween
(0.05%) (TBS-T), incubated with peroxidase-coupled
goat anti-mouse (Santa Cruz) or goat anti-rabbit
(Upstate, Ozyme) secondary antibody (1:20,000), washed
in TBS-T and revealed by chemiluminescence (Lumi-
GLO reagent and peroxide; Cell Signaling) and autora-
diography (X-Omat R film; Kodak). When necessary,
membranes were stripped with Blot Restore Kit (Chemi-
con International, Millipore, Saint-Quentin-en-Yvelines,
France) and reprobed with anti-tubulin (Cell Signaling)
or anti-actin (Santa Cruz) antibody to ensure equal
loading of the gels. Prestained molecular weight stan-
dards (Fermentas, Saint-Rémy-lès-Chevreuse, France)
were used.
Oligodeoxynucleotide pull-down
For in-cell hpdODN pull-down assays, cells were trans-
fected with the biotinylated hpdODNs (1 μg/ml, 6 h), as
described under oligonucleotide transfection, and then
lysed in cell lysis buffer (1% NP40, 50 mM Hepes, pH
7.6, 140 mM NaCl) containing salmon sperm DNA (1
μg/assay). Protein concentration was measured in the
samples. Extracts (250 μgo fp r o t e i np e rt u b e )w e r e
recovered on avidin-sepharose beads (50 μL) (NeutrAvi-
din, Pierce); beads were incubated for 30 min at 4°C in
b i n d i n gb u f f e r( 1 %N P 4 0 ,5 0m MH e p e s ,p H7 . 6 ,1 4 0
mM NaCl). After washing with binding buffer,
complexes were eluted in SDS sample buffer, separated
on SDS-PAGE (8%), and subjected to immunoblotting
using anti-STAT1 or anti-STAT3 antibodies (Cell Sig-
naling) and processed as above.
Immunocytochemistry
Cells were grown at 50-60% confluence in 8-well plates
(Lab-Tek, Nunc, Rochester, USA) to a density of 10
5 cells/
ml. Cells were transfected with fluorescein-labelled
hpdODNs, incubated (6 to 16 h), washed in PBS, fixed
with 3.7% formaldehyde for 15 min, permeabilized in 0.1%
Triton X-100 for 15 min and incubated in 5% FCS-0.1%
Tween- PBS for 1 h. Cells were stained with anti-STAT3
or anti-STAT1 antibody (Cell Signaling) (1:100) for 2 h,
then stained with an Alexa fluor 546-labeled secondary
antibody (Invitrogen) (1:200) for 90 min. Cells, counter-
stained with 4’,6 ’-diamidino-2-phenylindole (DAPI), were
mounted onto glass slides with Vectashield (Vectorlabs,
Clinsciences, Montrouge, France). Fluorescence images
were acquired using a Zeiss Axioplan 2 Deconvolution
microscope (Carl Zeiss, Le Pecq, France) and analyzed
with Metafer4 (Metasystems, Altlussheim, Germany).
Additional material
Additional file 1: Table S1 List of the contacts between STAT1,
STAT3 and DNA. Contacts were evaluated using the “Find clashes/
contacts” routine in Chimera with the default parameters (cut off = -0.4
Å and allowance for potentially hydrogen-bonded pairs = 0.0 Å). These
values allow the van der Waals radii in atom pairs to be taken into
account rather than interatomic distances alone.
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